RNA transfection

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

Retrieved on: 
Wednesday, August 4, 2021
Sarbecovirus, Zoonoses, Respiratory diseases, Viruses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, COVID-19

RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.

Key Points: 
  • RNAscope enables detection of RNA transcripts while retaining cellular morphology, allowing researchers to localize SARS-CoV-2 RNA directly in the tissues, including in the hyaline membranes, pneumocytes and macrophages of lung, and epithelial cells of airways.
  • The SARS-CoV-2 ASR will provide researchers and pathologists with a powerful technology for the detection of SARS-CoV-2 in fixed tissues.
  • During the pandemic, RNAscope probes have been an essential tool in elucidating the pathology of this devastating virus in over one hundred COVID-19 publications to date."
  • Bhatnagar J, Gary J, Reagan-Steiner S, Estetter LB, Tong S, et al.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Zoonoses, Bat virome, Viruses, Health, Hypersensitivity, Type IV hypersensitivity, DTH, Immunology, COVID-19, Severe acute respiratory syndrome, Tonix Pharmaceuticals

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development of CoviDTH, the Company's disposable point-of-care diagnostic tool that screens for a T cell response to SARS-CoV-2 in vaccinated patients or those exposed to SARS-CoV-2. Dr. Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.

Key Points: 
  • Barrios is a leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, as an immuno-diagnostic tool.
  • Dr. Barrios received her medical degree at La Laguna University, Tenerife, Spain and conducted her Clinical Immunology Residency at Puerta de Hierro Hospital.
  • [2] A Novel Application of Delayed-Type Hypersensitivity Reaction to Measure Cellular Immune Response in SARS-CoV-2 Exposed Individuals.
  • Also in development is CoviDTH, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19.

The Asia Group Serves as Key Strategic and Sales Advisor to Groundbreaking Collaboration Agreement to Bring mRNA Vaccine Technology to Vietnam

Retrieved on: 
Monday, August 2, 2021
Marketing strategy, Merchandising, Retail

We look forward to continuing to work with the TAG team as we look for new opportunities to expand our business."

Key Points: 
  • We look forward to continuing to work with the TAG team as we look for new opportunities to expand our business."
  • The Asia Group is the premier strategic advisory firm to the world's leading companies seeking to excel across the Indo-Pacific.
  • Vingroupis the largest private enterprise in Vietnam, with a market capitalization exceeding USD 21 billion and USD 4.7 billion in annual sales.
  • Founded in 1993, Vingroup's operations include a diversified portfolio of investments in real estate, retail, automotive manufacturing, and scientific research.

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Retrieved on: 
Monday, February 22, 2021
Manufacturing, Technology, Stem cells, Pharmaceutical, General Health, Infectious diseases, Genetics, Clinical trials, Other Technology, Other Manufacturing, Science, Biotechnology, Other Science, Health, Research, Nucleic acids, Branches of biology, Molecular biology, Gene expression, Biotechnology, Arcturus Therapeutics, RNA therapeutics, Messenger RNA, Sense, RNA, RNA vaccine, RNA transfection

Since the Companys inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of RNA through technological innovation.

Key Points: 
  • Since the Companys inception in 2013, Arcturus has been building proprietary expertise related to the manufacture of RNA through technological innovation.
  • The technology supports the Companys efforts to optimize the highly efficient manufacture of mRNA therapeutic candidates with an increased purity profile.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.